Conditions: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
Interventions: Biological: MK-1045; Biological: Zilovertamab vedotin; Biological: Rituximab; Biological: Rituximab biosimilar; Biological: Polatuzumab vedotin; Drug: Bendamustine; Biological: Lenalidomide; Biological: Tafasitamab; Biological: Rescue Medication – Biological; Drug: Rescue Medications – Drug; Other: Granulocyte-colony stimulating factor (G-CSF)
Sponsors: Merck Sharp & Dohme LLC
Not yet recruiting Conditions: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
Interventions: Biological: MK-1045; Biological: Zilovertamab vedotin; Biological: Rituximab; Biological: Rituximab biosimilar; Biological: Polatuzumab vedotin; Drug: Bendamustine; Biological: Lenalidomide; Biological: Tafasitamab; Biological: Rescue Medication – Biological; Drug: Rescue Medications – Drug; Other: Granulocyte-colony stimulating factor (G-CSF)
Sponsors: Merck Sharp & Dohme LLC
Not yet recruiting
